September 2021: For adult patients with Waldenström's macroglobulinemia, the FDA has approved zanubrutinib (Brukinsa, BeiGene) (WM).In ASPEN (NCT03053440), zanubrutinib was compared to ibrutinib in patients with MYD88 L265P mutat..
ເດືອນກໍລະກົດ 2021: Beta-thalassemia ແມ່ນສະພາບທີ່ສືບທອດມາຈາກການກາຍພັນໃນ gene ທີ່ກ່ຽວຂ້ອງກັບການຜະລິດອົງປະກອບຂອງ hemoglobin, ທາດໂປຼຕີນທີ່ຂົນສົ່ງອົກຊີເຈນໄປທົ່ວຮ່າງກາຍ. ການກາຍພັນເຫຼົ່ານີ້ຫ້າມ..
Because leukemia classification and prognosis stratification are complex, there is no one-size-fits-all treatment method, and it is necessary to combine careful classification and prognosis stratification to formulate treatment p..
On June 17-20, 2015, the 13th International Lymphoma Conference was successfully held in Switzerland. 3700 representatives from 90 countries participated in the event. At the meeting, the research on lymphoma was brilliant, not o..
Eddle and Pearlie Saddler, as his wife Pearlie hopes, "enjoy a regular life" in their South Carolina town. When they rested, Saddlers volunteered and participated in the service in the church. "We go there often, especially Eddi..
A review written by Young, MD, Anderson Cancer Center, USA explained the application of PD-1 inhibitor immunotherapy in B-cell lymphoma. (Blood. Online version on November 8, 2017. doi: 10.1182 / blood-2017-07-740993.)PD-1 immune..
A new study from McMaster University in Canada said that it has discovered a new treatment strategy for acute myeloid leukemia. By stimulating the production of fat cells in the bone marrow and adjusting the bone marrow microenvir..
The Cleveland Clinic of the United States Eric D. His et al. Reported that the diagnosis of peripheral T cell lymphoma (PTCL) in the United States varies greatly, and often lacks important phenotypic information to fully distingui..
Acalabrutinib is a second-generation tyrosine kinase (BTK) inhibitor, a newer drug that can improve the survival of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).The researchers believe that BTK inhibitors comb..
Mature T-cell tumors, such as non-Hodgkin T-cell lymphoma, are highly invasive and drug-resistant, and patients often have a poor prognosis. Recently, "Nature" series of two articles published a new interpretation of the pathogene..